Neuralace Medical

Neuralace Medical is a commercial-stage private company that has achieved FDA clearance for its flagship Axon Therapy® mPNS system, a first-of-its-kind, completely non-invasive neuromodulation device for chronic neuropathic pain. The technology uses high-intensity magnetic fields to target peripheral nerves without implants or injections, positioning it as a potential alternative to opioids and invasive surgical interventions. With published clinical data showing significant pain reduction, the company is targeting the vast chronic pain market with a therapy designed for ease of use in clinical settings. Leadership includes seasoned medtech executives focused on commercial growth and expanding the platform's indications.

Axon Therapy® magnetic Peripheral Nerve Stimulation (mPNS) - A non-invasive platform using a high-intensity, focused magnetic field to generate electrical currents in peripheral nerves for neuromodulation, without needles or implants.

Neuralace competes in the broader neuromodulation market dominated by large players like Boston Scientific, Abbott, and Nevro that sell invasive SCS and PNS systems. Its direct differentiation is non-invasiveness. It may face future competition from other non-invasive stimulation technologies (e.g., transcranial magnetic stimulation adapted for peripheral nerves) and from pharmaceutical therapies.